Gui Zhi Fu Ling Wan

Add Content

• Definition
• Introduction
• Signs & Symptoms
• Research Summary

Presentation Slides

---

Executive Summary

---

Write an executive summary in the form of a blog article on the topic of "Research into Chinese medicine treatment for Gui Zhi Fu Ling Wan" summarising the research below and using language that can be easily understood by patients and avoiding medical jargon using a professional and caring tone of voice.

Write an executive summary in the form of a blog article on the topic of "Researched Chinese medicine treatments for Gui Zhi Fu Ling Wan" summarising the research below in an objective and easy to understand way, and using language that can be easily understood by patients. Group the article into Chinese medicine treatments first, followed by nutrition and other treatments. Avoid using medical jargon and use a professional and caring tone of voice.

Write me a concise but easy to understand executive summary on the topic of "Chinese medicine treatments for Gui Zhi Fu Ling Wan" based on the following research that I will give you. Your summary should be 2 paragraphs long in Australian English spelling and include references to the studies.

A published in 2024 in the journal Journal of Ethnopharmacology found that Guizhi Fuling Wan, a traditional Chinese herbal formula, can inhibit endometriosis growth and enhance the effects of western medicines used to treat the condition. In the methodology, a bibliographic assessment of publications on "Guizhi Fuling Wan" and "endometriosis" indexed in international and chinese databases was conducted. Out of these, five pre-clinical studies and thirteen clinical were selected. Thereafter, targeted molecules of each herb in the formula were extracted from a Traditional Chinese Medicine Systems Pharmacology Database and compared with endometriosis-related genes from DisGeNET. To expose potential therapeutic mechanisms of Guizhi Fuling Wan, pathway and gene ontology analyses were performed using David Bioinformatics Resources. In the results discussion, it was found that both pre-clinical and clinical studies suggested that Guizhi Fuling Wan can inhibit the growth of endometriotic lesions by modulating immunity, apoptosis-regulating molecules, and angiogenesis-associated factors, while also enhancing the effects of western medicines for endometriosis. The formula likely achieves this through its impact on key pathways involved in diabetes complications, Kaposi sarcoma-associated herpesvirus infection, human cytomegalovirus infection, and atherosclerosis, which all regulate inflammation, angiogenesis, and apoptosis. The review also notes a strong connection between endometriosis and abnormal inflammatory, angiogenic, and apoptotic activities.

A published in 2022 in the journal Taiwanese Journal of Obstetrics and Gynecology found that Combining traditional Chinese medicine Guizhi Fuling Wan with western hormonal therapies can potentially reduce their individual effectiveness in treating endometriosis. In this study, endometriosis was induced in mice. This was achieved by suturing endometrial tissue onto the peritoneal wall of the subjects. The mice were then treated with varying combinations of Guizhi Fuling Wan (GFW), a traditional Chinese medicine, and current western hormonal therapies for a period of 28 days. The results show that the traditional Chinese medicine Guizhi Fuling Wan (GFW), hormonal therapies, and combinations of these two were able to inhibit the development of endometriosis. They also observed that these treatments, either alone or in combination, could inhibit the expression of Intercellular Adhesion Molecule 1 (ICAM-1) and Vascular Endothelial Growth Factor (VEGF). These agents could also reduce the population of macrophages in the peritoneal fluid while enhancing the B-cell population. However, when GFW was combined with hormonal therapies, it was observed that the efficiency of each agent individually was potentially reduced.

A Network Pharmacology published in 2021 in the journal Evidence-Based Complementary and Alternative Medicine found that Gui Zhi Fu Ling Wan treats adenomyosis by intervening in local estrogen signalling pathways and affecting estrogen resistance via myometrium signalling pathways. This study utilized network pharmacology, molecular docking and animal experiments to understand the treatment mechanisms of Guizhi Fuling Wan on adenomyosis. Initially, key indices and target components of the traditional Chinese medicine were identified through various databases, which resulted in isolation of 55 active ingredients and 44 targets specifically related to adenomyosis treatment. These components were then subjected to protein interaction analysis and compound-hub target network constructions. Main active elements and hub targets were subsequently studied with molecular docking tech. The pathway enrichment analysis showed that the medicinal effects were primarily linked to estrogen signaling, endocrine resistance, and a specific tyrosine kinase signaling pathway. The molecular docking revealed that significant compounds of Guizhi Fuling Wan had a strong binding ability with a couple of cellular receptors. Animal trials indicated that this medicine could reduce abnormal infiltration of specific cells without interrupting normal sexual cycles. These results point towards the importance of the estrogen signaling pathway and cell receptors in the treatment capabilities of Guizhi Fuling Wan.

A Study Protocol published in 2021 in the journal BMC Complementary Medicine and Therapies found that Gynoclear™, a formulation of six herbs, could potentially reduce the severity and duration of pain and other symptoms associated with endometriosis. The methodology consisted of a randomized, double-blind, placebo-controlled trial with a minimum of 90 participants across Australia who have confirmed endometriosis and moderate or greater pelvic pain. These participants were equally divided to receive either Gynoclear™ or a placebo. Gynoclear's active ingredients consist of six herbs, namely Safflower, Chinese cinnamon, Hoelen, Tree peony, Peony, and Red sage. The participants were required to document their pain experiences for a total of five months, which included a month of screening, two months of treatment, and a month post-treatment. The main variable being studied was the change in endometriosis-related pain. The results of the study aimed to establish the efficacy of Gynoclear™ in reducing endometriosis-related pain and other symptoms. Secondary outcomes encompassed change in health-related quality of life, alterations in the use of rescue analgesics, and changes in sexual discomfort and fatigue. The practicality and usefulness of Gynoclear™ intended to serve both healthcare professionals and individuals suffering from endometriosis.

A Experimental Study published in 2019 in the journal Frontiers in Pharmacology found that Gui Zhi Fu Ling Wan can potentially reduce and induce apoptosis in uterine leiomyomas cells. In the study, human uterine myoma cells (hUtMCs) were collected from patients who had undergone surgery for this condition. The viability of these cells was tested when exposed to various doses of Gyejibongnyeong-hwan (GBH). Determination of adequate concentration for the treatment was also performed, ensuring that it did not affect normal cells adversely. Western blotting was employed to identify the expression levels of certain proteins that indicate cellular apoptosis, while the levels of reactive oxygen species were evaluated through fluorescence microscopy. Finally, the researchers looked into the time-dependent anti-neoplastic effect of GBH in order to establish an appropriate treatment duration under a non-harmful concentration of the medication. The results showed that Gyejibongnyeong-hwan (GBH) drastically reduced the viability and number of hUtMCs within 48 hours in a dose-dependent manner. It was identified that the ratio of certain proteins and the expression of other apoptosis-related ones increased, suggesting that GBH induced cellular self-destruction in uterine leiomyomas. Moreover, it was shown that GBH noticeably increased the mitochondrial concentration of reactive oxygen species. Conversely, by using certain inhibitors along with GBH, the apoptotic effect mediated by GBH was mitigated. This evidence suggests that GBH could potentially trigger apoptosis of leiomyomas and hence, presents a promising therapeutic agent in managing uterine leiomyomas.

A Network Pharmacology published in 2019 in the journal Biomedicines found that Guizhi Fuling Wan, a traditional herbal formula, can improve peripheral blood flow in menopausal hot flush sufferers, despite not changing the frequency or severity of the flushes. The methodology used in this study involved a comprehensive literature search across 20 English and Chinese databases for relative clinical and experimental studies. From the nearly 13,000 studies identified, only 46 were evaluated as relevant and thus included in the review. These articles were comprised of seven clinical studies detailing Guizhi Fuling Wan's effects on menopausal hot flushes and 35 phytochemical analysis studies that identified the 169 chemical compounds in the herbal formula. Four experimental studies were also utilized to discover the potential therapeutic effects and target proteins/cytokines related to these hot flushes. The findings indicate that Guizhi Fuling Wan, despite exhibiting no significant impact on the frequency or severity of menopausal hot flushes, may have positive effects on peripheral blood flow. The blood flow improvements were specifically noted in the fingertips, jaw, and toes. Additionally, the analysis of the herbal formula revealed 169 distinct chemical compounds. Through experimental studies, potential therapeutic effects on target proteins/cytokines - including estrogen receptor beta with genetic variation, the calcitonin gene-related peptide receptor, and interleukin-8, were further highlighted. However, these therapeutic effects were inconsistent across different studies, which may be due to dosage differences and genotype variation.

A Systematic Review published in 2014 in the journal BMC Complementary Medicine and Therapies found that Guizhi Fuling formula shows potential in treating uterine fibroids. This comprehensive review analyzed 21 trials (including three meta-analyses and eight individual trials) regarding the effectiveness of Guizhi Fuling Formula combined with mifepristone in treating uterine fibroids. The results indicated potential benefits in reducing fibroid volume and uterine size compared to mifepristone alone. However, the overall methodological quality of the included trials was deemed poor, with issues such as unclear randomization procedures and lack of blinding. Further high-quality clinical trials with larger sample sizes are recommended to provide more conclusive evidence on the efficacy of this treatment approach for uterine fibroids.

A published in 2011 in the journal Journal of Acupuncture and Meridian Studies found that Gui-zhi-fu-ling-wan, a traditional Chinese medicine, can effectively alleviate hot flashes in young patients in a safe manner. For the methodology, this study was conducted retrospectively, examining the medical records of patients who visited the Department of Cardiovascular and Neurologic Disease, Kyung Hee Oriental Medical Center for hot flashes from between October 1, 2003, to October 1, 2008. Out of 60 cases reviewed, 37 were selected based on the inclusion criteria. The primary measure of improvement was assessed using the visual analog scale. In the discussion of results, it was noted that the mean improvement in symptoms was significant and a majority of patients experienced a 50% improvement. The secondary analysis revealed that the outcomes of differential diagnosis of cold and hot syndrome and blood stasis syndrome did not affect the scores. Importantly, only a trivial percentage of patients reported adverse events, indicating that Gui-zhi-fu-ling-wan may be a safe therapy for hot flashes.

A published in 2005 in the journal The American Journal of Chinese Medicine found that Gui-zhi-fu-ling-wan, a herbal therapy, depicts to be a viable alternative to hormone replacement therapy for treating hot flashes in post-menopausal women experiencing coldness in lower extremities. In this study, an examination of the connection between extremities' blood flow and hot flashes was conducted among 352 post-menopausal women aged between 46 and 58 who were showing climacteric complaints. 131 of these women, who were experiencing hot flashes, were treated either with HRT or Gui-zhi-fu-ling-wan, a type of herbal therapy. This investigation measured blood flow under the jaw, in the middle finger, and the third toe using laser doppler fluxmetry. Subsequent to the therapies, there was a notable decrease in the heightened blood flow under the jaw that is associated with hot flashes. However, the herbal therapy, Gui-zhi-fu-ling-wan, interestingly, increased blood flow in the lower extremities while the hormone replacement therapy did not. This suggests that Gui-zhi-fu-ling-wan does not uniformly affect the activity of the vasodilator neuropeptides on the sensory neurons of systemic peripheral vessels, thereby proving more effective in treating hot flashes accompanied with cold lower extremities.

Moderation Tools

---

Topic